Nuwellis Inc vs Philip Morris International Inc. — how do they compare? Nuwellis Inc trades at $1.52 (market cap $522.76K), while Philip Morris International Inc. trades at $186.22 (market cap $289.90B). The key difference: Philip Morris International Inc. is far larger — about 554556.6× Nuwellis Inc's market cap, and Philip Morris International Inc. pays a 3.16% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUWE | PM | |
|---|---|---|
Market Cap | $522.76K | $289.90B |
Sector | Technology | Consumer Staples |
52-Week High | $220.50 | $200.17 |
52-Week Low | $1.42 | $144.33 |
Enterprise Value | -$1.29M | $333.02B |
Dividend Yield | — | 3.16% |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
Philip Morris International (PM) trades at $186.22, down 1.77% with mixed technical signals. The company reported strong Q1 and Q2 2026 earnings beats but faces margin pressure from rising costs. Revenue grew to $40.65B in 2025 with a robust 25.56% net income margin. Analyst consensus remains bullish with a $211.17 price target, though recent news highlights challenges including a $500M impairment charge and increased illicit cigarette trade in Europe.
PM offers solid fundamentals with high profitability and dividend yield, but near-term headwinds from cost inflation and regulatory risks warrant caution. The stock's valuation at 25.54x P/E is reasonable given earnings growth potential, making it attractive for long-term investors despite current volatility.
Trailing returns across standard periods
Latest headlines on both assets
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →